58
Participants
Start Date
March 31, 2009
Primary Completion Date
August 31, 2010
Study Completion Date
June 30, 2016
brentuximab vedotin
1.8 mg/kg every 3 weeks by IV infusion
UZ Gasthuisberg, Leuven
Memorial Sloan Kettering Cancer Center, New York
Weill Cornell Medical College, New York
Institut Paoli Calmettes, Marseille
University of Miami Sylvester Comprehensive Cancer Center, Miami
Nationwide Children's Hospital, Columbus
Karmanos Cancer Institute / Wayne State University, Detroit
Mayo Clinic Rochester, Rochester
Northwestern University, Chicago
Washington University School of Medicine, St Louis
Baylor Sammons Cancer Center / Texas Oncology, Dallas
Hospital Saint Louis, Paris
Centre Henri Becquerel, Rouen
Rocky Mountain Cancer Centers, Denver
Stanford University Medical Center, Palo Alto
Oregon Health & Science University, Portland
University of Washington, Seattle
University of Alabama at Birmingham, Birmingham
MD Anderson Cancer Center / University of Texas, Houston
B.C Cancer Agency, Vancouver
Princess Margaret Hospital, Toronto
Christie Hospital NHS, Manchester
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
Seagen Inc.
INDUSTRY